Literature DB >> 20101429

Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab.

Taner Babacan1, Ahmet Mesut Onat, Yavuz Pehlivan, Gazi Comez, Metin Karakök.   

Abstract

Adult onset Still's Disease (ASD) is a systemic inflammatory disorder of unknown etiology characterized by chronic and fluctuant fever with accompanying rash, polyarthritis and involvement of multiple organs, especially lymphoid tissues. Although kidney involvement may appear in some cases of adult Still's disease, membranous glomerulonephyritis has not been described before. We herein report a 38-year-old man diagnosed with Still's disease with longstanding polyarthritis unresponsive to high-dose steroids and various immunosuppressive drugs for 5 years. He was referred to our clinic with bilateral pretibial edema on his legs. Urine examination revealed 10.5 g/day proteinuria with membranous glomerulonephritis and his renal biopsy came up with it. Infliximab was initiated, and his complaints were totally resolved also with a normal urine test in the following 3 months. To the best of our knowledge, this is the first report that clearly shows the efficacy of infliximab in a patient with refractory ASD with membranous glomerulonephyritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101429     DOI: 10.1007/s10067-009-1331-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  25 in total

1.  A case of adult onset Still's disease treated with infliximab.

Authors:  P Caramaschi; D Biasi; A Carletto; L M Bambara
Journal:  Clin Exp Rheumatol       Date:  2002 Jan-Feb       Impact factor: 4.473

2.  Vascular renal AA amyloidosis in adult Still's disease.

Authors:  F Rivera; C M Gil; M T Gil; E Batlle-Gualda; M Trigueros; J Olivares
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

3.  Infliximab in the treatment of adult Still's disease refractory to conventional therapy.

Authors:  L Cavagna; R Caporali; O Epis; F Bobbio-Pallavicini; C Montecucco
Journal:  Clin Exp Rheumatol       Date:  2001 May-Jun       Impact factor: 4.473

4.  Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.

Authors:  Der-Yuan Chen; Joung-Liang Lan; Fang-Ju Lin; Tsu-Yi Hsieh
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

Review 5.  Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

Authors:  C Mukhtyar; R Luqmani
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

6.  Urinary excretion of cytokines and complement SC5b-9 in idiopathic membranous glomerulonephritis.

Authors:  E Honkanen; A M Teppo; S Meri; T Lehto; C Grönhagen-Riska
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

7.  Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis.

Authors:  T Lehto; E Honkanen; A M Teppo; S Meri
Journal:  Kidney Int       Date:  1995-05       Impact factor: 10.612

Review 8.  NIH conference. Membranous nephropathy.

Authors:  H A Austin; T T Antonovych; K MacKay; D T Boumpas; J E Balow
Journal:  Ann Intern Med       Date:  1992-04-15       Impact factor: 25.391

9.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10

10.  Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy.

Authors:  R Thonhofer; A Soleiman; M Kriessmayr; U Thonhofer; E Wipfler; M Gaugg; S Eder; L Erlacher
Journal:  Scand J Rheumatol       Date:  2006 Nov-Dec       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.